Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Glenmark gets...

    Glenmark gets tentative nod from USFDA for epilepsy drug

    Written by savita thakur thakur Published On 2016-03-19T11:27:42+05:30  |  Updated On 19 March 2016 11:27 AM IST
    Glenmark gets tentative nod from USFDA for epilepsy drug
    New Delhi : Glenmark Pharmaceuticals said it has received tentative approval from the US health regulator for its generic version of Vimpat Oral Solution, used in treatment of epilepsy.

    "Glenmark Pharmaceuticals Inc, USA has been granted tentative approval by the US Food and Drug Administration (USFDA) for its Lacosamide Oral solution, 10 Mg/mL, the generic version of Vimpat Oral Solution, 10 Mg/mL of UCB, Inc," it said in a BSE filing.

    The company will market this product upon receiving final approval of Lacosamide Oral solution, 10 Mg/mL.

    "The patent listed in the Orange Book for Vimpat Oral Solution, 10 Mg/mL is scheduled to expire on March 17, 2022," it added.

    According to IMS Health sales data for the 12 months to January 2016, Vimpat has annual sales of around $55.4 million, Glenmark said.

    The company's current portfolio consists of 108 products authorised for distribution in the US marketplace and 61 Abbreviated New Drug Applications (ANDA) pending approval with the USFDA.

    Glenmark Pharmaceuticals shares were trading at Rs 787.20 in the morning deals on the BSE, down 2.95 per cent.

    Source : PTI
    abbreviated new drug applicationsANDAEpilepsyepilepsy drugGlenmarkLacosamide Oral solutionUS Food and Drug AdministrationUSFDAVimpat Oral Solution

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok